Researchers discover intake of FDA-approved drug modulates disease progression in Alzheimer’s disease model
Indiana University School of Medicine researchers have found that niacin limits Alzheimer’s disease progression when used in models in the lab, a discovery that could potentially pave the way toward therapeutic approaches to the disease.